The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to ... is a rapid-acting human insulin analog designed ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

Civica will utilize our US-based manufacturing operations in Petersburg, Virginia to produce prefilled pens and vials of insulin.” This collaboration is in addition to Biocon Biologics’ own insulin ...

as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar ...

Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting ...

Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under ... of producing prefilled pens and vials of insulin.